ADAMTS13 and thrombotic thrombocytopenic purpura: Further work to increase protein expression and duration of action is required, but we can postulate that the ADAMTS13-M5 variant may be able to last for longer than 5 days in humans and provide significant clinical benefit to acquired TTP patients.